Gland Pharma net profits were higher by 34% at Rs.260 crore in the Mar-21 quarter on the back of robust sales growth. Total revenues for the quarter came in 40% higher at Rs.888 crore in the Mar-21 quarter.
The vaccine vertical is anticipated to boost the prospects of Gland Pharma entering into the Biosimilar space. Gland Pharma had recently listed with its Rs.6,000 crore IPO.
Gland Pharma net profits were higher by 34% at Rs.260 crore in the Mar-21 quarter on the back of robust sales growth. Total revenues for the quarter came in 40% higher at Rs.888 crore in the Mar-21 quarter.
The vaccine vertical is anticipated to boost the prospects of Gland Pharma entering into the Biosimilar space. Gland Pharma had recently listed with its Rs.6,000 crore IPO.